Prevalence of Renal and Bone Risk Factors Among Individuals Prescribed Oral Pre-exposure Prophylaxis for HIV

Overview

Journal IJID Reg

Specialty Infectious Diseases

Date 2023 Feb 16

PMID 36793391

Authors

Sheldon D Fields

Joshua Gruber

Jamaal Clue

Gabriel Gomez Rey

Helena Diaz Cuervo

Affiliations

Soon will be listed here.

Abstract

Objectives: The only available oral pre-exposure prophylaxis (PrEP) regimens approved in the United States to prevent HIV infection during the period covered by this study were emtricitabine/tenofovir alafenamide (F/TAF) and emtricitabine/tenofovir disoproxil fumarate (F/TDF). Both agents have similar efficacy, however F/TAF exhibits improved bone and renal health safety endpoints over F/TDF. In 2021, the United States Preventive Services Task Force recommended individuals have access to the most medically appropriate PrEP regimen. To understand the impact of these guidelines, the prevalence of risk factors to renal and bone health was evaluated among individuals prescribed oral PrEP.

Methods: This prevalence study utilized the electronic health records of people prescribed oral PrEP between January 1, 2015 and February 29, 2020. Renal and bone risk factors (age, comorbidities, medication, renal function, and body mass index) were identified using International Classification of Diseases (ICD) and National Drug Code (NDC) codes.

Results: Among 40 621 individuals prescribed oral PrEP, 62% had ≥1 renal risk factor and 68% had ≥1 bone risk factor. Comorbidities were the most frequent (37%) class of renal risk factors. Concomitant medications were the most prominent (46%) class of bone-related risk factors.

Conclusions: The high prevalence of risk factors suggests the importance of their consideration when choosing the most appropriate regimen for individuals who may benefit from PrEP.

Citing Articles

Investigating and Practicing Orthopedics at the Intersection of Sex and Gender: Understanding the Physiological Basis, Pathology, and Treatment Response of Orthopedic Conditions by Adopting a Gender Lens: A Narrative Overview.

Biz C, Khamisy-Farah R, Puce L, Szarpak L, Converti M, Ceylan H Biomedicines. 2024; 12(5).

PMID: 38790936 PMC: 11118756. DOI: 10.3390/biomedicines12050974.

Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential.

Henderson A, Cholli P, Lampe M, Kourtis A Expert Rev Anti Infect Ther. 2024; 22(4):153-167.

PMID: 38517686 PMC: 11287786. DOI: 10.1080/14787210.2024.2334054.

References

Havens P, Perumean-Chaney S, Patki A, Cofield S, Wilson C, Liu N . Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. Clin Infect Dis. 2019; 70(4):687-691. PMC: 7319267. DOI: 10.1093/cid/ciz486. View

Glidden D, Mulligan K, McMahan V, Anderson P, Guanira J, Chariyalertsak S . Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis. J Acquir Immune Defic Syndr. 2017; 76(2):177-182. PMC: 5597476. DOI: 10.1097/QAI.0000000000001475. View

Ogbuagu O, Ruane P, Podzamczer D, Salazar L, Henry K, Asmuth D . Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021; 8(7):e397-e407. DOI: 10.1016/S2352-3018(21)00071-0. View

Coin A, Sergi G, Beninca P, Lupoli L, CINTI G, Ferrara L . Bone mineral density and body composition in underweight and normal elderly subjects. Osteoporos Int. 2001; 11(12):1043-50. DOI: 10.1007/s001980070026. View

Fields S, Tung E . Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review. Infect Dis Ther. 2021; 10(1):165-186. PMC: 7875561. DOI: 10.1007/s40121-020-00384-5. View

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock P, Leethochawalit M . Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381(9883):2083-90. DOI: 10.1016/S0140-6736(13)61127-7. View

Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J . Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367(5):399-410. PMC: 3770474. DOI: 10.1056/NEJMoa1108524. View

Braun L, Wentz A, Baker R, Richardson E, Tsai J . Racialized algorithms for kidney function: Erasing social experience. Soc Sci Med. 2020; 268:113548. DOI: 10.1016/j.socscimed.2020.113548. View

Kanis J, Johansson H, Johnell O, Oden A, De Laet C, Eisman J . Alcohol intake as a risk factor for fracture. Osteoporos Int. 2004; 16(7):737-42. DOI: 10.1007/s00198-004-1734-y. View

10.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

11.

Overman R, Yeh J, Deal C . Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2012; 65(2):294-8. DOI: 10.1002/acr.21796. View

12.

Dougherty G, Golden S, Gross A, Colantuoni E, Dean L . Measuring Structural Racism and Its Association With BMI. Am J Prev Med. 2020; 59(4):530-537. PMC: 8147662. DOI: 10.1016/j.amepre.2020.05.019. View

13.

Grohskopf L, Chillag K, Gvetadze R, Liu A, Thompson M, Mayer K . Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2013; 64(1):79-86. DOI: 10.1097/QAI.0b013e31828ece33. View

14.

Panday K, Gona A, Humphrey M . Medication-induced osteoporosis: screening and treatment strategies. Ther Adv Musculoskelet Dis. 2014; 6(5):185-202. PMC: 4206646. DOI: 10.1177/1759720X14546350. View

15.

Kim E, Kwon D, Lee B, Kim Y, Ahn Y, Yoon K . Frequency of osteoporosis in 46 men with methamphetamine abuse hospitalized in a National Hospital. Forensic Sci Int. 2009; 188(1-3):75-80. DOI: 10.1016/j.forsciint.2009.03.016. View

16.

Orth S, Hallan S . Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence?. Clin J Am Soc Nephrol. 2007; 3(1):226-36. DOI: 10.2215/CJN.03740907. View

17.

Drak D, Barratt H, Templeton D, OConnor C, Gracey D . Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service. PLoS One. 2019; 14(1):e0210106. PMC: 6336260. DOI: 10.1371/journal.pone.0210106. View

18.

McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015; 387(10013):53-60. PMC: 4700047. DOI: 10.1016/S0140-6736(15)00056-2. View

19.

Fong T, Lee B, Tien A, Chang M, Lim C, Ahn A . Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J Viral Hepat. 2018; 26(5):561-567. DOI: 10.1111/jvh.13053. View

20.

Hwang Y, Dixon S, Reiss J, Wald R, Parikh C, Gandhi S . Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014; 161(4):242-8. DOI: 10.7326/M13-2796. View